Want to see IN:NATCOPHARM full AI Analyst Report?

NATCO Pharma Limited (NATCOPHARM) Price & Analysis

16 Followers

NATCOPHARM Stock Chart & Stats

₹893.35

-₹7.80(-0.59%)

At close: Jan 08 4:00 PM EST

₹893.35

-₹7.80(-0.59%)

Day’s Range― - ―

52-Week Range₹789.30 - ₹1,226.10

Previous CloseN/A

Volume335.92K

Average Volume (3M)59.22K

Market Cap

₹167.04B

Enterprise Value₹160.46B

Total Cash (Recent Filing)₹40.77B

Total Debt (Recent Filing)₹2.61B

Price to Earnings (P/E)11.8

Beta1.00

Next Earnings

Aug 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.57%

Share Statistics

EPS (TTM)85.91

Shares Outstanding179,109,860

10 Day Avg. Volume63,709

30 Day Avg. Volume59,218

Financial Highlights & Ratios

PEG Ratio-0.51

Price to Book (P/B)1.95

Price to Sales (P/S)4.40

P/FCF Ratio13.03

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)42.07

Revenue Forecast (FY)₹32.40B

Bulls Say, Bears Say

Bulls Say

Business Model: Complex Generics & APIsNATCO's strategic emphasis on complex generics, differentiated dosage forms and APIs suggests durable competitive advantages versus commodity generic players. Complex products and API capabilities support higher pricing, regulatory barriers to entry, and recurring supply contracts across domestic and export markets.

High And Sustained MarginsConsistently elevated gross and net margins indicate lasting earnings power from product mix and manufacturing efficiencies. High margin structure gives the company flexibility to invest in R&D, support commercialization of complex launches, and withstand pricing pressure in commoditized segments over the medium term.

Conservative Balance Sheet & Cash GenerationVery low leverage and improving operating/free cash flow provide durable financial flexibility. Strong cash conversion (free cash flow ~72%–84% of net income) supports reinvestment, product development and potential opportunistic M&A without stressing the balance sheet in 2–6 months.

Bears Say

Revenue Volatility & Recent DeclineTop-line swings, including the 2026 revenue drop, signal exposure to timing of large product launches, regulatory approvals, or customer concentration. This makes medium-term forecasting and capacity planning harder and can cause earnings variability even as margins remain high.

Historical Earnings/cash VolatilityPast sharp profit and cash-flow swings (notably 2022) show the business can experience material operational or working-capital stress. Such episodic volatility increases execution risk for multi-quarter product development and commercialization plans, complicating capital allocation.

Concentration On Launch-driven EarningsReliance on a few high-impact, first-to-market or complex generic launches creates concentration risk. Missed approvals, competitive entrants or tender dynamics can lead to sharp revenue swings, making multi-quarter growth dependent on successful, timely commercialization.

NATCO Pharma Limited News

Natco Pharma plays down impact of Eris semaglutide deal after NSE query

NATCO Pharma Limited ( ($IN:NATCOPHARM) ) has issued an update. Natco Pharma has clarified to the National Stock...

4M ago

NATCO Pharma Publishes Postal Ballot Notice in Newspapers and Online

The latest update is out from NATCO Pharma Limited ( ($IN:NATCOPHARM) ). NATCO Pharma Limited has notified the...

4M ago

Natco Pharma’s Credit Ratings Reaffirmed Amid Market Challenges

The latest update is out from NATCO Pharma Limited ( ($IN:NATCOPHARM) ). Natco Pharma Limited has had its...

7M ago

Natco Pharma Ensures Regulatory Compliance with SEBI Regulations

The latest update is out from NATCO Pharma Limited ( ($IN:NATCOPHARM) ). Natco Pharma Limited has submitted a...

9M ago

Natco Pharma’s Kothur Facility Receives VAI Status from FDA

NATCO Pharma Limited ( ($IN:NATCOPHARM) ) has provided an update. Natco Pharma Limited announced that its pharmaceutical division...

10M ago

Natco Pharma Publishes 42nd AGM Details in Leading Newspapers

NATCO Pharma Limited ( ($IN:NATCOPHARM) ) has shared an update. Natco Pharma Limited has announced the publication of...

10M ago

Natco Pharma Declares Interim Dividend and Plans Capital Increase

The latest update is out from NATCO Pharma Limited ( ($IN:NATCOPHARM) ). Natco Pharma Limited’s Board of Directors...

11M ago

Natco Pharma Appoints New Senior VP of Operations

The latest announcement is out from NATCO Pharma Limited ( ($IN:NATCOPHARM) ). Natco Pharma Limited has announced the...

1y ago

NATCOPHARM FAQ

What was NATCO Pharma Limited’s price range in the past 12 months?

NATCO Pharma Limited lowest stock price was ₹789.30 and its highest was ₹1226.10 in the past 12 months.

What is NATCO Pharma Limited’s market cap?

NATCO Pharma Limited’s market cap is ₹167.04B.

When is NATCO Pharma Limited’s upcoming earnings report date?

NATCO Pharma Limited’s upcoming earnings report date is Aug 12, 2026 which is in 38 days.

How were NATCO Pharma Limited’s earnings last quarter?

NATCO Pharma Limited released its earnings results on May 29, 2026. The company reported ₹9.45 earnings per share for the quarter, missing the consensus estimate of ₹15.763 by -₹6.313.

Is NATCO Pharma Limited overvalued?

According to Wall Street analysts NATCO Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NATCO Pharma Limited pay dividends?

NATCO Pharma Limited pays a Quarterly dividend of ₹1.5 which represents an annual dividend yield of 0.57%. See more information on NATCO Pharma Limited dividends here

What is NATCO Pharma Limited’s EPS estimate?

NATCO Pharma Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NATCO Pharma Limited have?

NATCO Pharma Limited has 179,109,860 shares outstanding.

What happened to NATCO Pharma Limited’s price movement after its last earnings report?

NATCO Pharma Limited reported an EPS of ₹9.45 in its last earnings report, missing expectations of ₹15.763. Following the earnings report the stock price went down -13.512%.

Which hedge fund is a major shareholder of NATCO Pharma Limited?

Currently, no hedge funds are holding shares in IN:NATCOPHARM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NATCO Pharma Limited

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.